Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences (NBIX), has demonstrated a clear selling bias in his recent insider transactions, with no open-market purchases recorded in the past two years. Since 2024, Benevich has executed six sales totaling approximately $4.2 million, including a $1.68 million disposition on April 15, 2024, and a $905,880 sale on November 28, 2025. His most recent activity in February 2026 involved multiple transactions, primarily option exercises (Code F) with no accompanying sales, suggesting he may be holding acquired shares. The pattern shows periodic divestments, often clustered around February and November, with smaller sales like $115,940 on February 10, 2025, and $184,598 on January 31, 2025. While his historical buying totals $11.9 million versus $26.9 million in sales, the absence of recent purchases contrasts with continued option exercises—such as the $1.11 million transaction on February 13, 2026—indicating he retains equity exposure despite reducing his position. All activity remains confined to Neurocrine Biosciences, reflecting his long-term affiliation with the company.
AI-assisted summary